OncoMatch/Clinical Trials/NCT04090567
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Is NCT04090567 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cediranib and Ceralasertib for advanced breast carcinoma.
Treatment: Cediranib · Ceralasertib · Olaparib — This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: BRCA1 germline mutation
BRCA germline positive breast cancer
Required: BRCA2 germline mutation
BRCA germline positive breast cancer
Required: HER2 (ERBB2) wild-type
HER2 negative
Disease stage
Required: Stage III, IIIA, IIIB, IIIC, IV (AJCC v8)
Metastatic disease required
advanced/metastatic HER2 negative, BRCA germline positive breast cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: PARP inhibitor — (neo)adjuvant or metastatic
Patient should have previously treated with any PARP inhibitor ((neo)adjuvant or metastatic) setting) and must have remained on treatment for e/= 2 months prior to progression of disease.
Must have received: endocrine therapy
Estrogen receptor positive (ER+) patients must have progressed on a prior endocrine therapy or are considered inappropriate for any FDA approved endocrine therapies for ER+ breast cancer.
Cannot have received: Ceralasertib (Ceralasertib)
Prior exposure to Ceralasertib
Lab requirements
Blood counts
Hemoglobin (Hgb) ≥ 10.0 g/dL with no blood transfusion in the past 28 days; ANC ≥ 1.5 x 10^9/L with no GCSF administration within 28 days; Platelet count ≥ 100 x 10^9/L
Liver function
Total bilirubin ≤ 1.5 x institutional ULN; AST/ALT ≤ 3.0 x ULN unless liver metastases are present in which case ≤ 5x ULN
Patients must have normal organ and bone marrow function measured within 28 days (baseline screening) as defined below: Hemoglobin (Hgb) ≥ 10.0 g/dL with no blood transfusion in the past 28 days prior to the administration; Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L with no GCSF administration within 28 days prior to administration of study treatment; Platelet count ≥ 100 x 10^9/L; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤3.0 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify